Literature DB >> 6490716

Heparin and related glycosaminoglycans modulate the secretory phenotype of vascular smooth muscle cells.

R A Majack, P Bornstein.   

Abstract

Previous studies have established a role for heparin-like molecules in the regulation of vascular smooth muscle cell growth and migration in vitro. We present data indicating that the secretory phenotype of cultured rat aortic smooth muscle cells can be modulated by exogenous soluble heparin, heparan sulfate, and dermatan sulfate glycosaminoglycans. In the presence of these molecules, smooth muscle cells secrete increased amounts of two noncollagenous proteins (Mr 37,000 and 39,000). This effect can be mimicked by iota carrageenan and dextran sulfate but not by hyaluronic acid, chondroitin-4-sulfate, or chondroitin-6-sulfate. The inductive effect of heparin was dose-dependent and occurred rapidly (within 1 h) with maximal induction (three- to fivefold over controls) occurring after 10-12 h of treatment. The effect was rapidly reversible (within 1 h) and was not altered in the presence of actinomycin D, suggesting regulation at a posttranscriptional level. These data indicate that the biosynthetic expression of specific smooth muscle cell proteins may be determined, at least in part, by components of the smooth muscle cell extracellular matrix.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6490716      PMCID: PMC2113357          DOI: 10.1083/jcb.99.5.1688

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  14 in total

1.  A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels.

Authors:  W M Bonner; R A Laskey
Journal:  Eur J Biochem       Date:  1974-07-01

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Suppression by heparin of smooth muscle cell proliferation in injured arteries.

Authors:  A W Clowes; M J Karnowsky
Journal:  Nature       Date:  1977-02-17       Impact factor: 49.962

4.  How does the extracellular matrix direct gene expression?

Authors:  M J Bissell; H G Hall; G Parry
Journal:  J Theor Biol       Date:  1982-11-07       Impact factor: 2.691

Review 5.  The extracellular matrix and the control of proliferation of vascular endothelial and vascular smooth muscle cells.

Authors:  D Gospodarowicz; I Vlodavsky; N Savion
Journal:  J Supramol Struct       Date:  1980

6.  What controls smooth muscle phenotype?

Authors:  J H Chamley-Campbell; G R Campbell
Journal:  Atherosclerosis       Date:  1981 Nov-Dec       Impact factor: 5.162

7.  Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. Possible role of a platelet endoglycosidase.

Authors:  J J Castellot; L V Favreau; M J Karnovsky; R D Rosenberg
Journal:  J Biol Chem       Date:  1982-10-10       Impact factor: 5.157

8.  Purification and properties of human platelet heparitinase.

Authors:  G M Oosta; L V Favreau; D L Beeler; R D Rosenberg
Journal:  J Biol Chem       Date:  1982-10-10       Impact factor: 5.157

9.  Inhibition of rat arterial smooth muscle cell proliferation by heparin. II. In vitro studies.

Authors:  R L Hoover; R Rosenberg; W Haering; M J Karnovsky
Journal:  Circ Res       Date:  1980-10       Impact factor: 17.367

10.  Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth.

Authors:  J J Castellot; M L Addonizio; R Rosenberg; M J Karnovsky
Journal:  J Cell Biol       Date:  1981-08       Impact factor: 10.539

View more
  20 in total

1.  Perlecan regulates Oct-1 gene expression in vascular smooth muscle cells.

Authors:  M C Weiser; N A Grieshaber; P E Schwartz; R A Majack
Journal:  Mol Biol Cell       Date:  1997-06       Impact factor: 4.138

2.  Heparin-like glycosaminoglycans influence growth and phenotype of human arterial smooth muscle cells in vitro. I. Evidence for reversible binding and inactivation of the platelet-derived growth factor by heparin.

Authors:  G Fager; G Camejo; G Bondjers
Journal:  In Vitro Cell Dev Biol       Date:  1992-03

3.  Heparin-like glycosaminoglycans influence growth and phenotype of human arterial smooth muscle cells in vitro. II. The platelet-derived growth factor A-chain contains a sequence that specifically binds heparin.

Authors:  G Fager; G Camejo; U Olsson; G Ostergren-Lundén; G Bondjers
Journal:  In Vitro Cell Dev Biol       Date:  1992-03

4.  Modulation of mesangial cell migration by extracellular matrix components. Inhibition by heparinlike glycosaminoglycans.

Authors:  J M Person; D H Lovett; G J Raugi
Journal:  Am J Pathol       Date:  1988-12       Impact factor: 4.307

5.  Control of smooth muscle cell growth by components of the extracellular matrix: autocrine role for thrombospondin.

Authors:  R A Majack; S C Cook; P Bornstein
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

Review 6.  Proteoglycans in health and disease: structures and functions.

Authors:  A R Poole
Journal:  Biochem J       Date:  1986-05-15       Impact factor: 3.857

Review 7.  Heterogeneity of myofibroblast phenotypic features: an example of fibroblastic cell plasticity.

Authors:  A Schmitt-Gräff; A Desmoulière; G Gabbiani
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

8.  Glycosaminoglycan stimulation of calcium release from mouse calvariae. Specificity for hyaluronic acid and dermatan sulfate.

Authors:  D L Cochran
Journal:  Calcif Tissue Int       Date:  1987-08       Impact factor: 4.333

9.  The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells.

Authors:  S E Funk; E H Sage
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

10.  Inhibition of phosphatidylinositol 4-phosphate kinase by heparin. A possible mechanism for the antiproliferative effects of heparin.

Authors:  C D Smith; D Wen; S L Mooberry; K J Chang
Journal:  Biochem J       Date:  1992-02-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.